Analyst Summary
- bluebird bio, Inc. entered into an agreement to be acquired by Beacon Parent Holdings, L.P. and Beacon Merger Sub, Inc.
- Stockholders will receive $3.00 per share in cash.
- Stockholders will receive one contingent value right (CVR) per share, representing the right to receive a non-tradeable contingent payment of up to $6.84 in cash.
- The CVR payment is contingent upon achieving $600,000,000 in Net Sales in any consecutive 12-month period with respect to the Company’s Existing Products prior to December 31, 2027.
- The Board of Directors determined that the Merger Agreement and the transactions contemplated by the Merger Agreement are advisable, fair to and in the best interests of the Company and its stockholders.
- The company entered into the Fifth Amendment to its Loan and Security Agreement, dated as of March 15, 2024.
- The company entered into the Sixth Amendment to the LSA
Potential Implications
Stock Price
- The stock price may be affected by the tender offer and the potential for the contingent value right to be paid.